New tools and antibodies to map and target proteins on cell surfaces
Surfaceomic technologies and antibodies to probe cell surface proteomes and their interactomes at unprecedented small scale and high-resolution
['FUNDING_OTHER'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-11348890
Creating lab tools and antibodies to better find and act on proteins at cell surfaces to help people with cancer and neurodegenerative diseases.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11348890 on ClinicalTrials.gov |
What this research studies
Researchers are building new lab tools to map which proteins sit on cell surfaces and how they interact, even in very small groups of cells. They will generate highly specific antibodies and use patient-derived samples and stem-cell models grown from patients to study changes in cancer and neurodegeneration. A high-resolution labeling method (using Dexter Energy Transfer) will be used to reveal protein complexes and interaction partners such as those around EGFR. The work aims to discover new biomarkers and potential drug targets that could guide future tests and treatments.
Who could benefit from this research
Good fit: Ideal participants would be people with cancer or neurodegenerative conditions who can provide tissue or blood samples or agree to contribute cells for research.
Not a fit: People without cancer or neurodegenerative disease, or those unable or unwilling to provide samples, are unlikely to receive direct benefit from participating.
Why it matters
Potential benefit: If successful, this work could lead to better diagnostic markers and new targeted treatments that detect or block disease-related cell-surface proteins.
How similar studies have performed: Related surface-proteome and antibody approaches have produced useful biomarkers and therapies before, but the small-scale, ultra-high-resolution mapping methods planned here are relatively new.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WELLS, JAMES A — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: WELLS, JAMES A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Cancer Drug, Cancer Genes, Cancer-Promoting Gene, Cancers